Cyberonics Inc.
- CYBX
- NASDAQ
- Consumer Products
- Latest 47.73
- Currency US$
- Change 0.21
- Percent Change 0.442 %
- Volume 276,849
- Fri May 24, 2013 4:00 PM EDT NASDAQ data delayed 15 minutes.
The Globe and Mail
- Open 47.43
- Previous Close 47.52
- High 47.92
- Low 47.03
- Bidx0 --
- Askx0 --
- 52-week High 01/09 56.73
- 52-week Low 05/23 36.94
- Beta 0.553
- Market Cap 1,323.08M
- EPS 1.58
- P/E 30.21
- Forward P/E 24.731
- PEG 1.54
- Annual Dividend --
- Yield --
News
- Cyberonics To Report Fourth Quarter And Fiscal Year 2013 Results And Host Webcast And Conference Call On June 5, 2013
- Cyberonics Provides Update On Submission To CMS
- Cyberonics Reports Fiscal 2013 Third Quarter Results
- Cyberonics to Participate in Upcoming Investor Conferences
- Cyberonics to Report Fiscal Year 2013 Third Quarter Results and Host Webcast and Conference Call on February 22, 2013
Financials & Calendars
- Sales $243,590,000
- Earnings $45,480,000
- Return on Equity 21.19%
- Cash Flow --
- Cash $116,530,000
- Current Ratio 8.95
12 months ended Jan 31, 2013.
Trailing 12 month results shown above.
All data is in U.S. dollars.
- Assets $250,410,000
- Liabilities $26,010,000
- Liabilities-to-Equity Ratio 0.12
Price Ratios
- Price to Sales 5.43
- Price to Book 5.90
- Price to Cash Flow n/a
Event Calendar
| Event | Last | Next | ||
|---|---|---|---|---|
| Earnings | Feb 22 | $0.38 | Jun 5 | $0.42 |
| Surprises | Feb 22 | 23.68% | n/a | n/a |
| Dividends | n/a | n/a | n/a | n/a |
| Splits | n/a | -- | n/a | n/a |
12 months ended May 26, 2013.
A look at major corporate events and financial announcements that are coming up.
Company Information
About the Company
Cyberonics, Inc. was founded to design, develop and market medical devices for the treatment of epilepsy and other debilitating neurological disorders using a therapy, vagus nerve stimulation. The company's initial target market is epilepsy, the world's second most prevalent neurological disorder, which is characterized by seizures. Vagus nerve stimulation with the Cyberonics NCP System was approved for use as an adjunctive therapy in reducing the frequency of seizures in adults and adolescents with medically refractory partial onset seizures. (PRESS RELEASE)
Officers
- Hugh M. Morrison Chairman of the Board
- Daniel J. Moore President and Chief Executive
- Company Type: n/a
- Company Status: n/a
- Full-time Employees: n/a
-
Incorporation:
United States,
n/a -
Top 1000 Ranking:
Profit: n/a
Revenue: n/a
Assets: n/a
Head Office
100 CYBERONICS BLVDHOUSTON, TX
77058
Phone: (281)-228-7200
Fax: (281)-2189332
Ideas & Discussion
Live Discussion of CYBX on StockTwits